Claims for Patent: 6,423,340

Summary for Patent: 6,423,340

Title:	Method for the treatment of inflammatory bowel diseases
Abstract:	Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as relapse preventing therapy for Crohn's colitis in its chronic phase and Crohn's disease in the small intestine.
Inventor(s):	Ulmius; Jan (Lund, SE)
Assignee:	Aktiebolaget Draco (Sodertalje, SE)
Application Number:	09/159,301
Patent Claims:	1. A method for the prevention or treatment of a bowel disease selected from the group consisting of ulcerative colitis, Crohn's colitis in its active phase, Crohn's colitis in its chronic phase as relapse preventing therapy and Crohn's disease in the small intestine as relapse preventing therapy, which comprises the oral administration per 24-hour period of a controlled-release pharmaceutical formulation comprising 2-20 mg of a compound selected from budesonide and the 22-R epimer thereof and which will release the compound at the site of the disease to be treated, to a patient in need of such prevention or treatment. 2. A method according to claim 1, wherein the compound is budesonide. 3. A method according to claim 1, wherein the 2-20 mg of the compound administered in a 24-hour period are divided into 1 to 4 doses. 4. A method according to claim 3, wherein the compound is administered in a unit dose of from 0.25-20 mg. 5. A method according to claim 4, wherein the compound is administered in a unit dose of from 2-5 mg. 6. A method according to claim 4, wherein the compound is administered in a unit dose of 0.5, 1.0 or 2.0 mg. 7. A method according to claim 1, wherein the compound is the 22-R epimer of budesonide. 8. A method according to any one of claims 1-6 and 7, wherein the disease is ulcerative colitis. 9. A method according to claim 8, wherein the formulation is in a form which will release the compound in the colon. 10. A method according to claim 8, wherein the formulation is in a form which will release the compound over a period of from 25-50 hours. 11. A method according to claim 8, wherein the formulation is in a form which will release the compound over a period of from 25-50 hours. 12. A method according to any one of claims 1 to 6 and 7, wherein the condition to be treated is Crohn's disease of the ileum and the formulation is in a form which will release the compound in the small intestine. 13. A method according to claim 12, wherein the formulation is in a form which will release the compound over a period of from 1-50 hours. 14. A method according to claim 13, wherein the formulation is in a form which will release the compound over a period of from 5-10 hours.